48
Participants
Start Date
April 7, 2025
Primary Completion Date
February 28, 2027
Study Completion Date
October 31, 2027
AMX0114
Antisense oligonucleotides (ASOs) are a type of medicine that treats diseases by intercepting the mRNA messages sent within the cell, resulting in fewer specific proteins being made. AMX0114 is an ASO that targets the mRNA messenger that instructs the body to create a protein called calpain-2. Calpain-2 has been linked to the degeneration and death of neurons in many neurological diseases, including people living with sporadic ALS. AMX0114 is designed to reduce the levels of calpain-2, with the goal of slowing down the process that leads to neuron injury and death.
Placebo
Placebo
RECRUITING
Temple University of the Commonwealth System of Higher Education, Philadelphia
RECRUITING
Georgetown University Hospital Pasquerilla Healthcare Center, Washington D.C.
RECRUITING
Mayo Clinic in Florida, Jacksonville
RECRUITING
University of Florida, Gainesville
RECRUITING
Orlando Regional Medical Center, Orlando Health Neuroscience Institute, Orlando
RECRUITING
Alliance for Multispecialty Research, LLC, Knoxville
RECRUITING
Mayo Clinic in Rochester, Rochester
RECRUITING
Houston Methodist Neurological Institute, Houston
RECRUITING
University of California, San Diego, La Jolla
RECRUITING
Massachusetts General Hospital, Healey & AMG Center for ALS, Boston
RECRUITING
University of Calgary, Calgary
RECRUITING
McMaster University, Hamilton
RECRUITING
London Health Sciences Centre, London
RECRUITING
McGill University Health Centre - Centre for Innovative Medicine, Montreal
Lead Sponsor
Amylyx Pharmaceuticals Inc.
INDUSTRY